GLP-1 drugs linked to lower liver failure and death risks in elderly

Research published in the journal Age and Ageing indicates that glucagon-like peptide-1 (GLP-1) medications, commonly prescribed for diabetes and obesity, may significantly lower the risk of serious liver complications and premature death in older populations. The findings suggest these drugs offer protective benefits against specific hepatic outcomes in patients managing metabolic conditions.

Study scope and patient demographics

Investigators analyzed medical records from approximately 88,000 individuals diagnosed with metabolic-associated fatty liver disease. The cohort had an average age of around 72 years. Researchers divided the participants into two groups: half were currently taking GLP-1 therapies, while the remaining half did not use these medications.

Reduction in liver failure and hospitalization

The data revealed that users of GLP-1 drugs experienced a 28% decrease in the likelihood of developing liver failure, a critical complication where the organ ceases to function properly. Additionally, patients receiving these treatments showed a reduced tendency toward general hospital admissions compared to their non-using counterparts.

Mortality rates and adverse effects

The most prominent finding was a 45% reduction in all-cause mortality among those treated with GLP-1 medications relative to the control group. However, the study also identified potential downsides. Patients on these drugs had higher diagnosis rates for certain conditions, including osteoporosis and retinopathy, a disorder affecting the retina of the eye. No significant drop in the risk of heart attacks or strokes was observed between the two groups.

Mechanism of action and side effects

GLP-1 therapies function by mimicking the glucagon-like peptide-1 hormone, which assists the body in regulating hunger and satiety signals. This mechanism reduces appetite and slows digestion. While effective for weight management, the medications can cause side effects such as vomiting. Users require specialized monitoring to maintain weight loss results over time.